Description of technique for EUS-guided tissue acquisition in pancreatic cancer for comprehensive molecular profiling: Results of a randomized trial

Aims As theoretically actionable genomic lesions are found in 50% of pancreatic cancers which can impact clinical management in up to 30% of patients, there is increased focus on molecular profiling. Although EUS-FNB is an established method for pathological diagnosis in pancreatic cancers, technique for comprehensive molecular profiling (CMP) has not been described.